We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
+11.1%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$440M
AUM Growth
+$9.07M
Cap. Flow
-$6.96M
Cap. Flow %
-1.58%
Top 10 Hldgs %
52.42%
Holding
87
New
10
Increased
20
Reduced
29
Closed
4

Top Buys

Rank Stock Value
1
CMPS
Compass Pathways
CMPS
+$10.8M
2
NKTR icon
Nektar Therapeutics
NKTR
+$5.13M
3
LRMR icon
Larimar Therapeutics
LRMR
+$4.36M
4
BCAX
Bicara Therapeutics
BCAX
+$2.76M
5
FULC icon
Fulcrum Therapeutics
FULC
+$1.9M

Top Sells

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$9.76M
2
AXGN icon
Axogen
AXGN
+$7.38M
3
ATXS
Astria Therapeutics
ATXS
+$3.99M
4
RVMD icon
Revolution Medicines
RVMD
+$2.41M
5
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$2.25M

Sector Composition

Rank Sector Weight
1 Healthcare 87.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDWD icon
51
MediWound
MDWD
$174M
$1.52M 0.35%
94,405
-19,207
-17% -$334K
KIDS icon
52
OrthoPediatrics
KIDS
$648M
$1.52M 0.35%
+95,659
New +$1.67M
RARE icon
53
Ultragenyx Pharmaceutical
RARE
$2.61B
$1.28M 0.29%
61,100
+45,100
+282% +$1.02M
ENGN icon
54
enGene Therapeutics
ENGN
$114M
$1.28M 0.29%
187,353
+23,708
+14% +$211K
NGNE icon
55
Neurogene
NGNE
$723M
$1.14M 0.26%
56,635
+28,661
+102% +$555K
SPRY icon
56
ARS Pharmaceuticals
SPRY
$561M
$1.12M 0.25%
139,285
-50,780
-27% -$487K
CTMX icon
57
CytomX Therapeutics
CTMX
$732M
$1.08M 0.25%
+230,000
New +$1.17M
MAZE
58
Maze Therapeutics
MAZE
$1.51B
$1.04M 0.24%
+35,000
New +$1.54M
MLYS icon
59
Mineralys Therapeutics
MLYS
$2.27B
$1.04M 0.24%
38,490
– –
SCYX icon
60
SCYNEXIS
SCYX
$51.5M
$997K 0.23%
+135,870
New +$840K
ORIC icon
61
Oric Pharmaceuticals
ORIC
$1.44B
$945K 0.22%
98,724
-42,321
-30% -$480K
INSP icon
62
Inspire Medical Systems
INSP
$1.65B
$939K 0.21%
18,200
+9,600
+112% +$672K
PYPD icon
63
PolyPid
PYPD
$90.9M
$911K 0.21%
207,900
– –
TELA icon
64
TELA Bio
TELA
$28.9M
$893K 0.2%
1,441,029
– –
ZBIO
65
Zenas BioPharma
ZBIO
$1.86B
$831K 0.19%
+42,500
New +$954K
VRCA icon
66
Verrica Pharmaceuticals
VRCA
$85.4M
$813K 0.19%
153,712
-19,739
-11% -$126K
FATE icon
67
Fate Therapeutics
FATE
$300M
$660K 0.15%
550,000
– –
ANNX icon
68
Annexon
ANNX
$867M
$653K 0.15%
117,812
-155,000
-57% -$873K
ARAY icon
69
Accuray
ARAY
$33.2M
$652K 0.15%
1,680,508
+285,000
+20% +$176K
NAMS icon
70
NewAmsterdam Pharma
NAMS
$3.23B
$640K 0.15%
+20,000
New +$651K
ACET icon
71
Adicet Bio
ACET
$78.4M
$639K 0.15%
93,812
– –
BNTX icon
72
BioNTech
BNTX
$23.4B
$622K 0.14%
7,000
– –
PLRX icon
73
Pliant Therapeutics
PLRX
$66.3M
$614K 0.14%
+487,000
New +$615K
CGEN icon
74
Compugen
CGEN
$228M
$549K 0.12%
257,783
-14,619
-5% -$28.4K
OBIO icon
75
Orchestra BioMed
OBIO
$265M
$539K 0.12%
126,841
– –
1 2
3
4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, DAFNA Capital Management held 87 positions worth $440M, up 2.1% from $431M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

DAFNA Capital Management's Q1 2026 filing shows 10 new, 20 increased, 29 reduced and 4 closed positions. Its largest new stake was Fulcrum Therapeutics: 205,000 shares worth $1.57M. The largest sale was Cytokinetics, an estimated $9.76M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 87% a quarter earlier.

  • DAFNA Capital Management's largest Q1 2026 buy was Fulcrum Therapeutics: 205,000 shares worth $1.57M.
  • DAFNA Capital Management added most to Compass Pathways in Q1 2026, an estimated $10.8M increase.
  • DAFNA Capital Management's biggest Q1 2026 reduction was Cytokinetics, cutting an estimated $9.76M.
  • DAFNA Capital Management fully exited Astria Therapeutics in Q1 2026, selling an estimated $3.99M.
  • DAFNA Capital Management's ten largest holdings make up 52% of its $440M portfolio in Q1 2026.
  • DAFNA Capital Management opened 10 new positions and closed 4 in Q1 2026.
  • DAFNA Capital Management's portfolio value rose 2.1% quarter-over-quarter to $440M.

Based on DAFNA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.